BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Irvine KM, Wockner LF, Shanker M, Fagan KJ, Horsfall LU, Fletcher LM, Ungerer JP, Pretorius CJ, Miller GC, Clouston AD, Lampe G, Powell EE. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int 2016;36:370-7. [PMID: 26104018 DOI: 10.1111/liv.12896] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
2 Albazaz R, Guthrie JA. Virtual Special Issue - Chronic liver disease. Clin Radiol 2017;72:429-32. [PMID: 28438323 DOI: 10.1016/j.crad.2017.03.016] [Reference Citation Analysis]
3 Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019;39:924-32. [PMID: 30253043 DOI: 10.1111/liv.13974] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
4 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
5 Simbrunner B, Marculescu R, Scheiner B, Schwabl P, Bucsics T, Stadlmann A, Bauer DJM, Paternostro R, Eigenbauer E, Pinter M, Stättermayer AF, Trauner M, Mandorfer M, Reiberger T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int 2020;40:1713-24. [PMID: 32358998 DOI: 10.1111/liv.14498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Reference Citation Analysis]
7 Stasi C, Tsochatzis EA, Hall A, Rosenberg W, Milani S, Dhillon AP, Pinzani M. Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. Dig Liver Dis 2019;51:1001-7. [PMID: 30606698 DOI: 10.1016/j.dld.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Rasmussen DN, Thiele M, Johansen S, Kjærgaard M, Lindvig KP, Israelsen M, Antonsen S, Detlefsen S, Krag A; GALAXY., MicrobLiver consortia. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol 2021:S0168-8278(21)00411-6. [PMID: 34118335 DOI: 10.1016/j.jhep.2021.05.037] [Reference Citation Analysis]
9 Heo JY, Kim BK, Park JY, Kim DY, Ahn SH, Kim HS, Park YN, Han KH, Song K, Kim SU. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut Liver 2018;12:190-200. [PMID: 29069887 DOI: 10.5009/gnl17092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, Kin S, Phillips M, Herlihy AH, Kendall TJ, Brown RM, Neil DAH, Hübscher SG, Hirschfield GM, Fallowfield JA. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Sci Rep 2018;8:9189. [PMID: 29907829 DOI: 10.1038/s41598-018-27560-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
11 Barchetta I, Cimini F, De Gioannis R, Ciccarelli G, Bertoccini L, Lenzi A, Baroni M, Cavallo M. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. Diabetes Metab Res Rev 2018;34:e2998. [DOI: 10.1002/dmrr.2998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Day JW, Rosenberg WM. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med 2018;79:694-9. [DOI: 10.12968/hmed.2018.79.12.694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clin Ther 2021:S0149-2918(21)00256-3. [PMID: 34400007 DOI: 10.1016/j.clinthera.2021.07.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Grecian SM, McLachlan S, Fallowfield JA, Hayes PC, Guha IN, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Obes Sci Pract 2021;7:497-508. [PMID: 34631129 DOI: 10.1002/osp4.484] [Reference Citation Analysis]
15 Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. J Investig Med 2018;66:661-8. [PMID: 29167192 DOI: 10.1136/jim-2017-000609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
16 Valery PC, Powell EE. Engaging primary care clinicians in the assessment of NAFLD. Nat Rev Gastroenterol Hepatol 2019;16:458-60. [PMID: 31142817 DOI: 10.1038/s41575-019-0164-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Irvine KM, Wockner LF, Hoffmann I, Horsfall LU, Fagan KJ, Bijin V, Lee B, Clouston AD, Lampe G, Connolly JE, Powell EE. Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. PLoS One. 2016;11:e0167001. [PMID: 27861569 DOI: 10.1371/journal.pone.0167001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
18 Connoley D, Patel PJ, Hogan B, Tanwar S, Rhodes F, Parkes J, Burt A, Watkins J, Sievert W, Rosenberg W. The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. BMC Gastroenterol 2021;21:268. [PMID: 34182924 DOI: 10.1186/s12876-021-01795-5] [Reference Citation Analysis]
19 Gunes Yegin E, Durusoy SS, Ture Ozdemir F, Kombak EF, Ataizi-Celikel C, Ozdogan OC. Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis. Ann Hepatol 2019;18:833-40. [PMID: 31558418 DOI: 10.1016/j.aohep.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Bradshaw D, Gilleece Y, Verma S, Abramowicz I, Bremner S, Perry N. Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open 2020;10:e035596. [PMID: 32636281 DOI: 10.1136/bmjopen-2019-035596] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 de Vries EMG, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int 2017;37:1554-61. [PMID: 28267887 DOI: 10.1111/liv.13402] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
22 Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight 2018;3:120274. [PMID: 30046009 DOI: 10.1172/jci.insight.120274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
23 Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, Stuart KA, Brown NN, Saad N, Clouston A, Irvine KM, Russell AW, Valery PC, Williams S, Powell EE. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J 2018;48:144-51. [PMID: 29083080 DOI: 10.1111/imj.13667] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
24 López IC, Aroca FG, Bernal MDF, Mompeán JAL, Bernal ÁB, Martínez AMH, Barba EM, Velasco JAN, Paricio PP. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. Obes Surg 2017;27:2347-53. [PMID: 28229316 DOI: 10.1007/s11695-017-2606-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Saffioti F, Hall A, de Krijger M, Verheij J, Hübscher SG, Maurice J, Luong TV, Pinzani M, Ponsioen CY, Thorburn D. Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis. Liver Int 2021. [PMID: 34051052 DOI: 10.1111/liv.14979] [Reference Citation Analysis]
26 Fujiwara N, Liu P, Athuluri-divakar SK, Zhu S, Hoshida Y. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 3-25. [DOI: 10.1007/978-3-030-21540-8_1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Grecian SM, McLachlan S, Fallowfield JA, Kearns PKA, Hayes PC, Guha NI, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.Liver Int. 2020;40:2252-2262. [PMID: 32638496 DOI: 10.1111/liv.14590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]